No effect of bezafibrate in patients with CPTII and VLCAD deficiencies

J Inherit Metab Dis. 2015 Mar;38(2):373-4. doi: 10.1007/s10545-014-9779-3. Epub 2014 Oct 21.

Authors

Mette Cathrine Ørngreen¹, John Vissing, Pascal Laforét

Affiliation

¹ Neuromuscular Clinic and Research Unit, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, mette.cathrine.oerngreen.01@rh.regionh.dk.

PMID: 25331908
DOI: 10.1007/s10545-014-9779-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Acyl-CoA Dehydrogenase, Long-Chain / deficiency*
Bezafibrate / therapeutic use*
Carnitine O-Palmitoyltransferase / deficiency*
Congenital Bone Marrow Failure Syndromes
Fatty Acids / metabolism*
Humans
Lipid Metabolism, Inborn Errors / drug therapy*
Lipolysis / drug effects*
Metabolism, Inborn Errors / drug therapy*
Mitochondrial Diseases / drug therapy*
Muscular Diseases / drug therapy*

Substances

Fatty Acids
Acyl-CoA Dehydrogenase, Long-Chain
Carnitine O-Palmitoyltransferase
Bezafibrate

Supplementary concepts

Carnitine palmitoyl transferase 2 deficiency
VLCAD deficiency